New drug combo aims to spare esophagus in cancer patients
NCT ID NCT06869226
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining the drug camrelizumab with chemotherapy before surgery can help people with esophageal cancer keep their esophagus instead of having it removed. About 283 adults with early-stage esophageal cancer will receive the treatment and be monitored for cancer recurrence or progression. The goal is to see if this approach is safe and effective for organ preservation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Can surgery for stomach or esophageal cancer cloud the mind?
- Virtual patients could revolutionize cancer drug testing
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?